A Phase 2 interventional study of Estradiol and placebo in Menopause, Vulvovaginal Atrophy and Painful Intercourse, sponsored by TherapeuticsMD. Completed at 1 site in United States. Open to female participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-12-14.
Sponsored by TherapeuticsMD · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.
Among the 56 studies in Dyspareunia with a site in United States, this one is the 29th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2013, is one of 7 in phase 2, and was the 19th registered.
159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.
Browse Dyspareunia studies →8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 40–90 · Women only · Healthy volunteers
Azure Biotech Inc. · Sites in United States
Ages 45–60 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 40 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 14 · Phase 4 8
First in 2004; this study’s year is marked. 4 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 64 across 127 interventional studies indexed under Dyspareunia.
Median enrollment 60 across the 53 interventional studies, 200 across the 3 observational. Of the 38 that completed or were terminated, 20 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 56 have an industry lead sponsor. The 10 most frequent:
TherapeuticsMD is the lead sponsor of 6 studies on the registry; none are open to participants now.
TherapeuticsMD has 2 studies filed under Dyspareunia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dyspareunia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197568Azure Biotech Inc.Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women | 2026-12-31 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Dyspareunia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study was designed to evaluate the efficacy and safety of TX-12-004-HR 10 μg in treating moderate to severe symptoms of vaginal atrophy associated with menopause after 14 days of treatment, and to estimate the effect size and variability of vulvovaginal atrophy endpoints. In addition, the systemic exposure to estradiol from single and multiple doses of TX-12-004-HR was to be investigated.
This study was a randomized, double-blind, placebo-controlled trial to evaluate safety and efficacy of the TX-12-004-HR formulation in reducing moderate to severe symptoms of vaginal atrophy associated with menopause and to investigate the systemic exposure to estradiol following once daily intravaginal administrations of TX-12-004-HR for 14 days.
Postmenopausal subjects who met the study entry criteria were randomized to one of two treatment groups (TX-12-004-HR or Placebo). During the Screening period subjects were asked to self-assess the symptoms of vulvar and/or vaginal atrophy, including vaginal dryness, vaginal and/or vulvar irritation/itching, dysuria, vaginal pain associated with sexual activity and vaginal bleeding associated with sexual activity. Subjects with at least one self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy identified by the subject as being most bothersome to her were eligible to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a baseline evaluation requirements:
At least one self-assessed moderate to severe symptom of vulvar and/or vaginal atrophy from the following list that is identified by the subject as being most bothersome to her:
Be judged by the Principal Investigator or Sub-investigator as being in otherwise generally good health based on a pre-study medical evaluation performed within 28 days prior to the initial dose of study medication. The medical evaluation findings must include:
Exclusion Criteria:
Have used estrogen alone or estrogen/progestin for any of the following time periods:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estradiol 10 μg vaginal softgel capsule
Drug: Estradiol
Placebo vaginal softgel capsule
Drug: placebo
1 10 µg capsule inserted vaginally for 14 days.
Also known as: 17β-estradiol
1 placebo capsule inserted vaginally for 14 days.
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells)
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells)
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells)
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Vaginal pH
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom
The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Vaginal Bleeding Associated With Sexual Activity
Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color)
Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity)
Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).
Time frame: Baseline to 15 days post-treatment
Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness)
Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).
Time frame: Baseline to 15 days post-treatment
Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions)
Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).
Time frame: Baseline to 15 days post-treatment
| Milestone | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Started | 24 | 26 |
| Completed | 24 | 24 |
| Not completed | 0 | 2 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Percentage of Parabasal Cells | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells) | -54.4 ± 4.6 | -4.8 ± 4.6 |
| Percentage of Superficial Cells | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Superficial Cells) | 35.2 ± 4.7 | 8.8 ± 4.7 |
| Percentage of Intermediate Cells | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Intermediate Cells) | 18.7 ± 4.7 | -3.5 ± 4.7 |
| pH | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Vaginal pH | -0.97 ± 0.1 | -0.34 ± 0.1 |
The severity of the most bothersome VVA symptom was self-assessed by each subject using a VVA questionnaire. The questionnaire has a 4-point scoring scale with: None=0, Mild=1, Moderate=2, and Severe=3. The lower the score, the least bothersome it is to the subject.
| units on a scale | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Severity of the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom | -1.043 ± 0.2 | -1.042 ± 0.2 |
Total number (N=10) of participants analyzed within each treatment group who were sexually active at both Baseline and Day 15 and provided a response at both visits.
| participants | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Bleeding/ No Bleeding (Success) | 2 | 1 |
| Bleeding/ Bleeding (Failure) | 0 | 3 |
| No Bleeding/ Bleeding (Failure) | 0 | 1 |
| No Bleeding/ No Bleeding (No Change) | 8 | 5 |
Outcome was measured by using a severity scale. No Atrophy is pink in color (0). Mild atrophy is lighter in color (1). Moderate atrophy is pale in color (2). Severe atrophy is transparent, either no color or inflamed (3).
| units on a scale | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Color) | -0.199 ± 0.1 | -0.009 ± 0.1 |
Outcome was measured by using a severity scale. No Atrophy=normal(0). Mild atrophy=vaginal surface bleeds with scraping(1). Moderate atrophy=vaginal surface bleeds with light contact(2). Severe atrophy=vaginal surface has petechiae before contact and bleeds with light contact(3).
| units on a scale | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Integrity) | -0.342 ± 0.1 | 0.176 ± 0.1 |
Outcome was measured by using a severity scale. No Atrophy has rogation and elasticity of vault(0). Mild atrophy has poor rogation with some elasticity noted of vaginal vault(1). Moderate atrophy is smooth, some elasticity of vaginal vault(2). Severe atrophy is smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)(3).
| units on a scale | Treatment 1 | Treatment 2 |
|---|---|---|
| Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Epithelial Surface Thickness) | -0.034 ± 0.1 | -0.133 ± 0.1 |
Outcome was measured by using a severity scale. No Atrophy has normal clear secretions noted on vaginal walls(0). Mild atrophy has superficial coating of secretions, difficulty with speculum insertion(1). Moderate atrophy is scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain(2). Severe atrophy has none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain(3).
| units on a scale | TX-12-004-HR 10μg | Placebo |
|---|---|---|
| Analysis of Change From Baseline to Day 15 in Investigator Assessment of the Vaginal Mucosa (Assessment of Vaginal Secretions) | -0.643 ± 0.1 | -0.274 ± 0.1 |
Collected over Adverse events were collected for 14 days (study duration). Subjects with AEs that were ongoing at study completion or study withdrawal were followed until resolution or for 30 days after the last dose of study medication.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TX-12-004-HR | — | 0/24 (0%) | 13/24 (54.2%) |
| Placebo | — | 0/26 (0%) | 4/26 (15.4%) |
| Event | TX-12-004-HR | Placebo |
|---|---|---|
| Vaginal dysplasiaReproductive system and breast disorders | 4/24 | 0/26 |
| Hot flushReproductive system and breast disorders | 2/24 | 0/26 |
| Vaginal haemorrhageReproductive system and breast disorders | 0/24 | 2/26 |
| Blood pressure increasedBlood and lymphatic system disorders | 1/24 | 0/26 |
| Eye ContusionEye disorders | 1/24 | 0/26 |
| NephrolithiasisRenal and urinary disorders | 1/24 | 0/26 |
| Vulvovaginal burning sensationReproductive system and breast disorders | 1/24 | 0/26 |
| Vulvovaginal pruritusReproductive system and breast disorders | 1/24 | 0/26 |
| Vaginal dischargeReproductive system and breast disorders | 1/24 | 0/26 |
| Vulvovaginal painReproductive system and breast disorders | 1/24 | 0/26 |
| Age, Continuous(years) | Estradiol 10 μg Daily for 14 Days | Placebo Daily for 14 Days | Total |
|---|---|---|---|
| Mean | 62.4 ± 5.7 | 62.3 ± 7.0 | 62.3 ± 6.4 |
| Sex/Gender, Customized(participants) | Estradiol 10 μg Daily for 14 Days | Placebo Daily for 14 Days | Total |
|---|---|---|---|
| Female | 24 | 26 | 50 |
| Race (NIH/OMB)(Participants) | Estradiol 10 μg Daily for 14 Days | Placebo Daily for 14 Days | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 21 | 24 | 45 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Estradiol 10 μg Daily for 14 Days | Placebo Daily for 14 Days | Total |
|---|---|---|---|
| United States | 24 | 26 | 50 |
| BMI (kg/m^2)(kg/m^2) | Estradiol 10 μg Daily for 14 Days | Placebo Daily for 14 Days | Total |
|---|---|---|---|
| Mean | 26.4 ± 3.9 | 27.2 ± 3.3 | 26.8 ± 3.6 |
The record gives a start of Jul 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol
TherapeuticsMD